Kairos Pharma Ltd. (KAPA)
NYSE: KAPAHealthcareBiotechnologyUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
KAPA stock chart
Technical analysisKey statistics
All statistics- Market cap
- $3.25M
- EPS (TTM)
- -$1.96
- Dividend yield
- None
- 52-week range
- 0.848 – 9.24
- Day range
- 0.92 – 1.24
- Volume / Avg
- 5.77M / 602.89K
- Beta
- —
- Shares outstanding
- 3.39M
52-week range
KAPA stock today
Kairos Pharma (KAPA) closed at $0.9595 on Oct 8, up 10.29% (+$0.0895), versus the S&P 500's 0.47% decline. Volume was 9.6x the average at 5.77M shares, a sign of unusually heavy trading. Shares are 89.6% below their 52-week high of $9.24 and 13.1% above the 52-week low of $0.848, near the bottom of the past year's range.
Kairos Pharma has posted a net loss over the last twelve months (EPS of -$1.96), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Kairos Pharma
Company profileKairos Pharma, Ltd., a clinical-stage biopharmaceutical company, develops immunotherapy and cell therapies for the treatment of cancer. The company offers therapeutics, including antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. It also develops ENV 105, an antibody therapeutic that is in a Phase 2 clinical trial for prostate cancer patients resistant to androgen-targeted therapy, as well as in a Phase 1 clinical trial for non-small cell lung cancer.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. John S. Yu M.D., Ph.D.
- Headquarters
- Los Angeles, CA
- Employees
- 1
- IPO year
- 2024
- Website
- kairospharma.com
Analyst forecast
ForecastConsensus (2 analysts)
none
Avg. price target
$49.00+5006.83%
- Strong buy 1
- Buy 1
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Kairos Pharma peers
Healthcare sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| APVOAptevo Therapeutics Inc. | 1.80 | -2.17% | $3.26M | vs KAPA |
| CVKDCadrenal Therapeutics Inc. | 0.9296 | -4.39% | $3.32M | vs KAPA |
| MBIOMustang Bio Inc. | 0.417 | -7.37% | $3.16M | vs KAPA |
| CMNDClearmind Medicine Inc. | 6.60 | 0.00% | $3.35M | vs KAPA |
| XRTXXORTX Therapeutics Inc. | 1.85 | +6.02% | $3.36M | vs KAPA |
| SLXNSilexion Therapeutics Corp | 0.2349 | -7.37% | $3.40M | vs KAPA |
| REVBRevelation Biosciences Inc. | 0.7739 | -6.55% | $3.08M | vs KAPA |
| SXTP60 Degrees Pharmaceuticals Inc. | 0.9725 | -11.59% | $3.42M | vs KAPA |
Indexes, lists and sector
Appears in lists
Kairos Pharma stock FAQ
What is Kairos Pharma's stock price today?
KAPA last traded at $0.9595 as of Oct 8, 4:00 PM EDT, up 10.29% on the day. Prices are delayed at least 15 minutes.
Who is Kairos Pharma's CEO?
Dr. John S. Yu M.D., Ph.D. is the chief executive officer of Kairos Pharma Ltd., which has about 1 employees.
What is the KAPA 52-week high?
The 52-week high for KAPA is $9.24 and the 52-week low is $0.848. The stock is currently 89.6% below its high.